The Journal of
Clinical Psychiatry

Empowering mental health professionals with peer-reviewed psychiatric research and insights

Back to top Open menu arrow
Current Issue Archives Authors Reviewers

Page 35

More JCP Articles

JCP
Mechanisms of Treatment of Bipolar Disorder and Borderline Personality Disorder: Brain Imaging Research
Meta-Analysis

March 27, 2023

Different brain regions were changed with psychotherapy versus medication. The findings may help with predicting treatment efficacy and identifying treatment biomarkers in these disorders.
, , , et al
JCP
Gestational Exposure to Benzodiazepines and Z-Hypnotics and Risk of ASD and ADHD
Clinical and Practical Psychopharmacology

March 27, 2023

Dr Chittaranjan Andrade, MD, discusses two new studies examining whether gestational exposure to benzodiazepine and hypnotics increases ASD and ADHD risk.
JCP
Diagnosing and Treating Alzheimer Disease During the Early Stage
Academic Highlights

March 22, 2023

Many new therapies for early-stage AD have made their way onto the scene that can delay onset of the disease and/or slow down progression. Find out the how, what,…
,
JCP
Olanzapine/Samidorphan Mitigates Weight Gain in Early Illness
Original Research

March 22, 2023

In patients with early-phase schizophrenia or bipolar disorder, combination olanzapine and samidorphan resulted in less weight gain at week 12 than olanzapine alone. Antipsychotic efficacy was similar between the…
, , , et al
JCP
In Memoriam: Robert M. A. Hirschfeld, MD
In Memoriam

March 20, 2023

Robert M. A. Hirschfeld is remembered as a pioneer in the phenomenology and treatment of bipolar disorder.
JCP
Repurposing Psychiatric Drugs
Narrative Review

March 20, 2023

Drugs labeled as “psychotropic” often have widespread reach and impact throughout the brain and body. Thus, many of these drugs could be repurposed for non-psychiatric indications of high public…
, , , et al
JCP
The GABA Pathway and New Clinical Trial Data in MDD and PPD
Supplement Article

March 16, 2023

Studies evaluating neuroactive steroid GABA-A receptor positive allosteric modulators demonstrate promising results for the treatment of MDD and PPD.
,
JCP
Protective Effect of Clozapine on Suicide
Original Research

March 15, 2023

Clozapine, which has shown promise in reducing suicidal behavior in schizophrenia, also appears to lower the odds of suicide death in the general population.
, , , et al
JCP
Neighborhood Vulnerability in First-Episode Psychosis
Original Research

March 13, 2023

Psychosocial difficulties in people with first-episode psychosis could be related to a lack of resources in the area where they live.
, , , et al
JCP
Doxazosin for the Treatment of PTSD and AUD
Original Research

March 8, 2023

This study is the first to evaluate doxazosin, an α1-adrenergic antagonist, in veterans with both PTSD and alcohol use disorder.
, , , et al
JCP
When and How to Use Lithium Augmentation for MDD
ASCP Corner

March 8, 2023

With its antisuicidal effect and low cost, lithium can be an effective alternative to other MDD augmentation strategies when antidepressants are not enough.
, ,
JCP
NNT, NNH, and LHH for Lumateperone
Original Research

March 6, 2023

The benefit-risk assessment of lumateperone was favorable as measured by number-needed-to-treat and number-needed-to-harm analyses.
, , , et al

Expert Consensus on Aripiprazole LAIs in Clinical Practice

Read the full report
Figure. Image of a syringe on two vials highlights aripiprazole monohydrate LAI clinical use in Bipolar I Disorder.

Subscribe to read
more articles

Subscribe